DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20161752

Impact of the underlying cause and co-morbid conditions on the outcome of hepatic encephalopathy

Ahmed H. Abdelraheem, Amar B. Elhussein, Aamir A. Magzoub, Walid G. Babikr

Abstract


Background: Hepatic encephalopathy (HE) is a serious neuropsychiatric complication of acute and chronic liver diseases. This study aimed at identifying liver diseases and co-morbidity conditions associated with hepatic encephalopathy (HE) and their impact on patient`s mortality (the outcome).

Methods: A hospital-based, prospective study enrolled 76 patients admitted with HE conducted at Ibn Sina specialized gastroenterology hospital, Sudan, from January 2010 to May 2011. Personal data, clinical presentation, underlying liver disease, precipitants, co-morbid conditions and the outcome of HE were obtained from the inpatients’ hospital records.

Results: A total of 76 patients were included, 62 males (81.5%) and 14 females (18.5%) aged between 13 and 84 years old. Hepatitis B virus (HBV) was the most common cause of the liver disease (36.8%), followed by HCV (11.8%). Clinically, 53 patients (69%) had impaired level of consciousness. Infection was the most common risk factor for HE (54%) followed by electrolyte disturbance (42%). Overall mortality within one to three weeks following the admission was (50%). The higher percentage of mortality was seen inpatients with late stage autoimmune hepatitis, followed by HCC and in co-morbid conditions like renal impairment (58.8%).

Conclusion: HE is associated with a high mortality despite proper management in specialized hospitals. The mortality tends to increase in the presence of comorbid condition.

 


Keywords


Hepatic encephalopathy, Viral hepatitis, Chronic liver disease

Full Text:

PDF

References


Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35(3):716-21.

Gadour MOEH, Kalaefa AMS. hepatic encephalopathy; high light. JMS. 2007; 2(1):49-56.

Stahl J. Studies of the blood ammonia in liver disease, its diagnostic, prognostic, and therapeutic significance. Ann Intern Med. 1963;58:1-24.

Ortiz M, Jacas C, Cordoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol. 2005;42(suppl):S45.

Groeneweg M, Quero JC, De Bruijn I, Hartmann IJ, Essink-bot ML, Hop WC, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology. 1998;28(1):45-9.

Prakash R and Mullen K.D. Nat. Mechanisms, diagnosis and management of hepatic encephalopathy. Gastroenterol. Hepatol. 2010;7(9),515-25.

Kramer L, Tribl B, Gendo A, Zauner C, Schneider B, Ferenci P, et al. Partial pressure of ammonia versus ammonia in hepatic encephalopathy. Hepatology. 2000;31(1):30-4.

Schafer DF, Jones EA. Hepatic encephalopathy and the gamma-aminobutyric-acid neurotransmitter system. Lancet. 1982;1(8262):18-20.

Hayat AS, Shaikh N, Memon F. Identification of Precipitating Factors in Hepatic Encephalopathy Patients at Liaquat University Hospital Jamshoro, World Applied Sciences Journal. 2010;8(6):661-6.

Gitlin N, Lewis DC, HinMey L. The diagnosis and prevalence of subclinical hepatic encephalopathy in apparently healthy ambulant, non-shunted patients with cirrhosis. J Hepatol. 1986;3(1):75-82.

Blei AT. Treatment of hepatic encephalopathy. Lancet. 2005;365(9468):385-1386.

Patidar KR, Bajaj JS. Covert and overt hepatic encephalopathy: diagnosis and management. Clin Gastroenterol Hepatol. 2015;13 (12):2048-61.

Mas A, Rodés J, Sunyer L, Rodrigo L, Planas R, Vargas V, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003;38(1):51-8.

Córdoba J, López-Hellín J, Planas M, Sabín P, Sanpedro F, Castro F, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol. 2004;41(1):38-43.

Bongaerts G, Severijnen R, Timmerman H. Effect of antibiotics, prebiotics and probiotics in treatment for hepatic encephalopathy. Med Hypotheses. 2005;64(1):64-8.

Elfaki AMH. Aetiology, complications, and preventive measures of liver cirrhosis; Elobeid Hospital; West Sudan, Sudan. JMS. 2008;3(1):25-9.

Mudaw HMY. Epidemiology of viral hepatitis in Sudan. Clinical and Experimental Gastroenterology. 2008;1:9-13.

Devrajani BR, Shah SZ, Devrajani T, Kumar D. Precipitating factors of hepatic encephalopathy at a tertiary care hospital Jamshoro, Hyderabad. J Pak Med Assoc. 2009;59(10):683-84.

Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet. 2010;376:190-201.

Gupta R, Agarwal SR, Jain M, Malhotra V, Sarin SK. Autoimmune hepatitis in the Indian subcontinent: 7 years’ experience. Journal of gastroenterology and hepatology. 2001;16(10):1144-8.

Munoz SJ. Driving with minimal hepatic encephalopathy: real world consequences. Am J Gastroenterol. 2007;102(9):1910-1.

Alam I, Razaullah, Haider I. Spectrum of Precipitating factors of Hepatic Encephalopathy in liver cirrhosis. Pakistan J. Med. Res 2005;44(2):96-9.

Jepsen P, Vilstrup H, Andersen PK, Lash TL, Sørensen HT. Comorbidity and survival of Danish cirrhosis patients: a nationwide population-based cohort study. Hepatology. 2008;48:214-20

Garg H, Kumar A, Garg V, Sharma P, Sharma BC, Sarin SK. Clinical profile and predictors of mortality in patients of acute- on- chronic liver failure. Dig and Liver dis. 2012;44(2):166-171.

Onyekwere CA, Ogbera AO, Hameed L. Chronic liver disease and hepatic encephalopathy: Clinical profile and outcomes. Niger J Clin pract. 2011;14(2):181-5.